Industry
Biotechnology
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 11:44 am
Portfolio Pulse from Avi Kapoor
July 16, 2024 | 9:51 am
Portfolio Pulse from Benzinga Insights
July 05, 2024 | 3:00 pm
Portfolio Pulse from Benzinga Insights
June 13, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 8:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.